Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 8—August 2023
Research

Economic Evaluation of Wastewater Surveillance Combined with Clinical COVID-19 Screening Tests, Japan

Byung-Kwang YooComments to Author , Ryo Iwamoto, Ungil Chung, Tomoko Sasaki, and Masaaki Kitajima
Author affiliations: Waseda University, Saitama, Japan (B.-K. Yoo); Kanagawa University of Human Services, Kanagawa, Japan (B.-K. Yoo, U. Chung); Shionogi & Co. Ltd. and AdvanSentinal Inc., Osaka, Japan (R. Iwamoto); The University of Tokyo, Tokyo, Japan (U. Chung); Independent consultant, Shiga, Japan (T. Sasaki); Hokkaido University, Hokkaido, Japan (M. Kitajima)

Main Article

Table 3

One-way sensitivity analyses of the base-case analysis of the incidence parameter in an economic evaluation of wastewater surveillance combined with clinical COVID-19 screening tests, Japan*

Incidence† Relative value of option 2
Option 1
 Option 2
 Incremental cost§ Incremental benefit¶ Relative ROI#
Cost Benefit ROI‡ Cost Benefit ROI‡
10 $67.04 $1.39 0.02 $53.60 $1.14 0.02 –$13.44 –$0.25 54
50 $67.04 $7.03 0.10 $53.61 $5.94 0.11 –$13.44 –$1.09 12
100 $67.05 $14.09 0.21 $53.61 $11.94 0.22 –$13.43 –$2.15 6
400 $67.07 $56.43 0.84 $53.66 $47.94 0.89 –$13.41 –$8.49 1.58
445 $67.08 $62.78 0.94 $53.67 $53.34 0.99 –$13.41 –$9.44 1.42
450 $67.08 $63.49 0.95 $53.67 $53.94 1.01 –$13.41 –$9.54 1.40
475 $67.08 $67.01 0.999 $53.67 $56.94 1.06 –$13.41 –$10.07 1.33
480 $67.08 $67.72 1.010 $53.67 $57.54 1.07 –$13.41 –$10.18 1.32
500 $67.08 $70.54 1.05 $53.68 $59.94 1.12 –$13.40 –$10.60 1.26
600 $67.09 $84.65 1.26 $53.69 $71.94 1.34 –$13.40 –$12.71 1.05
630 $67.09 $88.89 1.32 $53.70 $75.54 1.41 –$13.39 –$13.35 1.004
635 $67.09 $89.59 1.34 $53.70 $76.14 1.42 –$13.39 –$13.45 0.996
700 $67.10 $98.77 1.47 $53.71 $83.94 1.56 –$13.39 –$14.83 0.90
1,000 $67.12 $141.11 2 $53.75 $119.94 2 –$13.37 –$21.16 0.63
2,000 $67.20 $282.23 4 $53.91 $239.95 4 –$13.29 –$42.29 0.31
5,000 $67.45 $705.62 10 $54.37 $599.96 11 –$13.07 –$105.66 0.12
10,000 $67.85 $1,411.26 21 $55.14 $1,199.97 22 –$12.71 –$211.29 0.06

*Option 1 is clinical tests only; option 2 is wastewater surveillance and clinical tests. If an option is cost-saving compared with its comparator, the option’s ROI is estimated to exceed 1. The comparator of options 1 and 2 is do-nothing. All monetary values were expressed in 2022 US dollars. ROI, return on investment. †Disease incidence per day per 1 million residents in the area. ‡ROI is benefit divided by cost for each option. §Incremental cost is the cost of option 2 minus cost of option 1. A negative value of incremental cost indicates that option 2 has a lower cost or is cost-saving, compared with option 1. This could be interpreted as option 2’s relative benefit. ¶Incremental benefit is the benefit of option 2 minus benefit of option 1. A negative value of incremental benefit indicates that option 2 has a lower benefit compared with option 1, which could be interpreted as option 2’s relative cost. #Relative ROI is incremental cost divided by incremental benefit.

Main Article

Page created: June 02, 2023
Page updated: July 20, 2023
Page reviewed: July 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external